ArticleScientific reports2025
The associations between maternal glycolipid metabolism and fetal growth in term births.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative metabolomics of paired maternal-cord samples identifies pathway-level divergence.Metabolomics : Official journal of the Metabolomic Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This retrospective cohort study of 8,446 term pregnancies investigated the associations between maternal glycolipid metabolism and fetal growth. Neonates were classified as SGA, LGA, or AGA. Maternal triglycerides (TG), fasting plasma glucose (FPG), and the Triglyceride-Glucose (TyG) index were examined in relation to birth weight and SGA/LGA risks across trimesters using linear regression and generalized linear models. Group-based trajectory modeling was applied to the TyG index to identify metabolic patterns, and restricted cubic spline analyses assessed nonlinear associations between the third-trimester TyG and abnormal fetal growth. Higher maternal TG, FPG, and the TyG index were associated with increased birth weight and elevated LGA risk, with effects stronger in the GDM group than in the non-GDM group. Elevated TyG levels were consistently linked to reduced SGA risk and progressively higher LGA risk across trimesters, with LGA odds ratios of 1.32, 1.66, and 2.55 for the first, second, and third trimesters, respectively. Restricted cubic spline analyses revealed a J-shaped relationship between the third-trimester TyG and abnormal fetal growth. These findings indicate that maternal glycolipid metabolism influences fetal growth, with the TyG index serving as an integrated marker of maternal triglyceride-glucose status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.